Cargando…
Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study
BACKGROUND: Cyclic guanosine monophosphate (cGMP) is a second messenger regulated through natriuretic peptide and nitric oxide pathways. Stimulation of cGMP signaling is a potential therapeutic strategy for heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular dis...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033823/ https://www.ncbi.nlm.nih.gov/pubmed/31928156 http://dx.doi.org/10.1161/JAHA.119.013966 |
_version_ | 1783499748031856640 |
---|---|
author | Zhao, Di Guallar, Eliseo Vaidya, Dhananjay Ndumele, Chiadi E. Ouyang, Pamela Post, Wendy S. Lima, Joao A. Ying, Wendy Kass, David A. Hoogeveen, Ron C. Shah, Sanjiv J. Subramanya, Vinita Michos, Erin D. |
author_facet | Zhao, Di Guallar, Eliseo Vaidya, Dhananjay Ndumele, Chiadi E. Ouyang, Pamela Post, Wendy S. Lima, Joao A. Ying, Wendy Kass, David A. Hoogeveen, Ron C. Shah, Sanjiv J. Subramanya, Vinita Michos, Erin D. |
author_sort | Zhao, Di |
collection | PubMed |
description | BACKGROUND: Cyclic guanosine monophosphate (cGMP) is a second messenger regulated through natriuretic peptide and nitric oxide pathways. Stimulation of cGMP signaling is a potential therapeutic strategy for heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). We hypothesized that plasma cGMP levels would be associated with lower risk for incident HFpEF, any HF, ASCVD, and coronary heart disease (CHD). METHODS AND RESULTS: We conducted a case–cohort analysis nested in the ARIC (Atherosclerosis Risk in Communities) study. Plasma cGMP was measured in 875 participants at visit 4 (1996–1998), with oversampling of incident HFpEF cases. We used Cox proportional hazard models to assess associations of cGMP with incident HFpEF, HF, ASCVD (CHD+stroke), and CHD. The mean (SD) age was 62.4 (5.6) years and median (interquartile interval) cGMP was 3.4 pmol/mL (2.4–4.6). During a median follow‐up of 9.9 years, there were 283 incident cases of HFpEF, 329 any HF, 151 ASCVD, and 125 CHD. In models adjusted for CVD risk factors, the hazard ratios (95% CI) associated with the highest cGMP tertile compared with lowest for HFpEF, HF, ASCVD, and CHD were 1.88 (1.17–3.02), 2.18 (1.18–4.06), 2.84 (1.44–5.60), and 2.43 (1.19–5.00), respectively. In models further adjusted for N‐terminal‐proB‐type natriuretic peptide, associations were attenuated for HFpEF and HF but remained statistically significant for ASCVD (2.56 [1.26–5.20]) and CHD (2.25 [1.07–4.71]). CONCLUSIONS: Contrary to our hypothesis, higher cGMP levels were associated with incident CVD in a community‐based cohort. The associations of cGMP with HF or HFpEF may be explained by N‐terminal‐proB‐type natriuretic peptide, but not for ASCVD and CHD. |
format | Online Article Text |
id | pubmed-7033823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70338232020-02-27 Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study Zhao, Di Guallar, Eliseo Vaidya, Dhananjay Ndumele, Chiadi E. Ouyang, Pamela Post, Wendy S. Lima, Joao A. Ying, Wendy Kass, David A. Hoogeveen, Ron C. Shah, Sanjiv J. Subramanya, Vinita Michos, Erin D. J Am Heart Assoc Original Research BACKGROUND: Cyclic guanosine monophosphate (cGMP) is a second messenger regulated through natriuretic peptide and nitric oxide pathways. Stimulation of cGMP signaling is a potential therapeutic strategy for heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). We hypothesized that plasma cGMP levels would be associated with lower risk for incident HFpEF, any HF, ASCVD, and coronary heart disease (CHD). METHODS AND RESULTS: We conducted a case–cohort analysis nested in the ARIC (Atherosclerosis Risk in Communities) study. Plasma cGMP was measured in 875 participants at visit 4 (1996–1998), with oversampling of incident HFpEF cases. We used Cox proportional hazard models to assess associations of cGMP with incident HFpEF, HF, ASCVD (CHD+stroke), and CHD. The mean (SD) age was 62.4 (5.6) years and median (interquartile interval) cGMP was 3.4 pmol/mL (2.4–4.6). During a median follow‐up of 9.9 years, there were 283 incident cases of HFpEF, 329 any HF, 151 ASCVD, and 125 CHD. In models adjusted for CVD risk factors, the hazard ratios (95% CI) associated with the highest cGMP tertile compared with lowest for HFpEF, HF, ASCVD, and CHD were 1.88 (1.17–3.02), 2.18 (1.18–4.06), 2.84 (1.44–5.60), and 2.43 (1.19–5.00), respectively. In models further adjusted for N‐terminal‐proB‐type natriuretic peptide, associations were attenuated for HFpEF and HF but remained statistically significant for ASCVD (2.56 [1.26–5.20]) and CHD (2.25 [1.07–4.71]). CONCLUSIONS: Contrary to our hypothesis, higher cGMP levels were associated with incident CVD in a community‐based cohort. The associations of cGMP with HF or HFpEF may be explained by N‐terminal‐proB‐type natriuretic peptide, but not for ASCVD and CHD. John Wiley and Sons Inc. 2020-01-13 /pmc/articles/PMC7033823/ /pubmed/31928156 http://dx.doi.org/10.1161/JAHA.119.013966 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Zhao, Di Guallar, Eliseo Vaidya, Dhananjay Ndumele, Chiadi E. Ouyang, Pamela Post, Wendy S. Lima, Joao A. Ying, Wendy Kass, David A. Hoogeveen, Ron C. Shah, Sanjiv J. Subramanya, Vinita Michos, Erin D. Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study |
title | Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study |
title_full | Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study |
title_fullStr | Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study |
title_full_unstemmed | Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study |
title_short | Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study |
title_sort | cyclic guanosine monophosphate and risk of incident heart failure and other cardiovascular events: the aric study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033823/ https://www.ncbi.nlm.nih.gov/pubmed/31928156 http://dx.doi.org/10.1161/JAHA.119.013966 |
work_keys_str_mv | AT zhaodi cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT guallareliseo cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT vaidyadhananjay cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT ndumelechiadie cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT ouyangpamela cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT postwendys cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT limajoaoa cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT yingwendy cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT kassdavida cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT hoogeveenronc cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT shahsanjivj cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT subramanyavinita cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy AT michoserind cyclicguanosinemonophosphateandriskofincidentheartfailureandothercardiovasculareventsthearicstudy |